Navigation Links
TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
Date:4/23/2012

RESEARCH TRIANGLE PARK, N.C., April 23, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today a strategic relationship with Microsoft Corp. that will help it extend the reach of its drug discovery process. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries will apply to identify inhibitors of 25 biological targets.

TeraDiscoveries will use its Inverse Design software that runs computational models to quickly scan virtual chemical libraries to find the strongest inhibitors of a specific biological target. The process identifies novel drug candidates that feature good clinical trial properties and demonstrate low probability of toxic side effects.

"Designing new drugs that bind to a specified protein target requires finding the best molecule in a vast chemical space. Our approach searches this space much more efficiently and cost-effectively than traditional methods," says Ed Addison, CEO of TeraDiscoveries. "Our strategic relationship with Microsoft enables us to partner with smaller pharmaceutical or medical research companies in the pursuit of these molecules."

"Windows Azure is an open and flexible cloud platform that has the scale and reliability to enable the type of computing power needed by software like Inverse Design," says Doug Hauger, General Manager, Windows Azure Business Development, Microsoft. "We're pleased to be able to support the work done by TeraDiscoveries to help advance its drug discovery process."

Companies can license Inverse Design and run it on Windows Azure to design, discover, or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also provides drug discovery services for companies seeking outside assistance.

TeraDiscoveries will be presenting Inverse Design in booth MP-10 at the Bio-IT World Conference & Expo taking place April 24 to 26, 2012, in Boston.

About TeraDiscoveries, Inc.

TeraDiscoveries is a drug discovery company located in Research Triangle Park, North Carolina. The company's Inverse Design software enables a paradigm shift to dramatically improve upon traditional drug discovery and design methods. This proprietary software combined with cloud computing enables the rapid and accurate discovery of novel drug candidates to serve as a catalyst for improved health and well-being. Visit www.teradiscoveries.com or contact Ed Addison at eaddison@teradiscoveries.com or (910) 398-1200.  

All product and company names herein may be trademarks of their respective owners.


'/>"/>
SOURCE TeraDiscoveries, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverseons Founder and SAB Member Published in PNAS
2. Inverseon Announces Positive Phase IIa Asthma Study
3. TissuGlu® Surgical Adhesive Named 2012 Medical Design Excellence Awards Finalist
4. Ultragenyx Granted Orphan Designations in Europe for Two Lead Product Candidates, UX001 for HIBM and UX003 for MPS 7
5. GlobalSpec Medical Equipment Design Online Trade Show and Event Draws More Than 1,100 Attendees
6. Brainlab Curve Wins Coveted Red Dot Award: Product Design 2012
7. Government Rule Designed to Limit CT Scans in ERs Is Unreliable, Invalid and Inaccurate, Says ACEP
8. Sensors in Design Summit Launches at Design West
9. Medical Design & Manufacturing Conference to be Launched in Texas in March 2012
10. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
11. Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... COLUMBUS, Ohio, Feb. 4, 2016 Mettler-Toledo International ... results for 2015.  Provided below are the highlights: ... the quarter compared with the prior year.  Reported sales ... in the quarter. , Net earnings per diluted ... in the prior- year period.  Adjusted EPS was $4.65, ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown that building ... the frequency and level of relapse. , At the 2016 iaedp ... will explore the critical tasks of the recovery phase and beyond including relapse ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
Breaking Medicine News(10 mins):